Company intelligence / Profile preview

M:M Bio

Abingdon, Oxfordshire, United Kingdommoleculetomedicine.com ↗

Ownership: Private
Development stage: Preclinical

Overview

M:M Bio has co-founded, incubated, and secured funding for three biotech companies specializing in immuno-oncology and targeted oncology. Its latest venture is ThirtyFiveBio, which raised $20 million in seed funding to develop small molecule drugs targeting GPCR35. The group provides operational support across its ecosystem of startups

Therapeutic areas: Oncology
Modalities: Immuno-oncology therapies (likely includes small molecules, biologics, targeted therapies)
Industry: Drug Discovery Services

Drug pipeline

1 asset

PTT-4256

Pre-clinical

Indications: Solid tumors

Beyond the preview

Go deeper on M:M Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M:M Bio.

Explore the full profile